Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

被引:120
作者
Fu, L [1 ]
Cheng, YC [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
关键词
hepatitis B virus (HBV); L(-)SddC (3TC); drug resistance; YMDD motif; site-directed mutagenesis; mutations outside YMDD motif;
D O I
10.1016/S0006-2952(98)00050-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
L(-)SddC (3TC) has been shown to be the most promising nucleoside analogue used for the treatment of hepatitis B virus (HBV) infection. Unfortunately, it has been reported that about 12% of HBV-infected patients experience a recurrence of HBV after a period of treatment with 3TC. Point mutations were detected in the HBV polymerase of those viruses from 3TC-resistant patients. A common mutation occurred at methionine in the YMDD motif. In this report, we present mutants that were generated from the HBV genome (adr subtype) by site-directed mutagenesis based on clinical reports from other investigators. With the transient transfection system, it was found that by changing methionine to valine or isoleucine at the YMDD motif, the viral DNA replication would be more than 100-fold less efficient than that of the wild-type virus. Some additional mutations outside the YMDD motif could enhance the replication of the virus containing a YMDD mutation. Various levels of resistance to 3TC were observed in HBV mutants containing point mutations both inside and outside the YMDD motif. These results suggest. that the mutations outside the YMDD motif compensate the YMDD mutation to some extent for the viral replication and may also contribute to clinical viral resistance to 3TC. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1567 / 1572
页数:6
相关论文
共 22 条
  • [1] Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
    Aye, TT
    Bartholomeusz, A
    Shaw, T
    Bowden, S
    Breschkin, A
    McMillan, J
    Angus, P
    Locarnini, S
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 (05) : 1148 - 1153
  • [2] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
    Bartholomew, MM
    Jansen, RW
    Jeffers, LJ
    Reddy, KR
    Johnson, LC
    Bunzendahl, H
    Condreay, LD
    Tzakis, AG
    Schiff, ER
    Brown, NA
    [J]. LANCET, 1997, 349 (9044) : 20 - 22
  • [3] HIGH-LEVEL RESISTANCE TO (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE IN-VITRO IS DUE TO ONE AMINO-ACID SUBSTITUTION IN THE CATALYTIC SITE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    BOUCHER, CAB
    CAMMACK, N
    SCHIPPER, P
    SCHUURMAN, R
    ROUSE, P
    WAINBERG, MA
    CAMERON, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) : 2231 - 2234
  • [4] Hepatitis B virus induced hepatocellular carcinoma: Possible roles for HBx
    Cromlish, JA
    [J]. TRENDS IN MICROBIOLOGY, 1996, 4 (07) : 270 - 274
  • [5] CULLEN BR, 1992, METHOD ENZYMOL, V216, P362
  • [6] HIV RESISTANCE TO REVERSE-TRANSCRIPTASE INHIBITORS
    DECLERCQ, E
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) : 155 - 169
  • [7] A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION
    DIENSTAG, JL
    PERRILLO, RP
    SCHIFF, ER
    BARTHOLOMEW, M
    VICARY, C
    RUBIN, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) : 1657 - 1661
  • [8] INHIBITION OF THE REPLICATION OF HEPATITIS-B VIRUS INVITRO BY 2',3'-DIDEOXY-3'-THIACYTIDINE AND RELATED ANALOGS
    DOONG, SL
    TSAI, CH
    SCHINAZI, RF
    LIOTTA, DC
    CHENG, YC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) : 8495 - 8499
  • [9] Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] in vitro
    Fischer, KP
    Tyrrell, DLJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) : 1957 - 1960
  • [10] Fu L, 1996, ACTA BIOCH BIOPH SIN, V28, P590